In this video, Annie Cowan, BA, Dana-Farber Cancer Institute, Boston, MA, briefly discusses reasons for improving risk stratification models for patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma and the goal of these novel models in preventing disease progression. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.